Updates

Hutchison China Meditech - Broker says 600p sum of parts

September 2011

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

An outlicencing deal of HCM's new HMPL-004 drug for inflammatory bowel disease ahead of it moving into phase 3 is overdue. This is expected any time and is the trigger that we think will get the share price moving as it will also hopefully be the precursor for listing the drug division on NASDAQ. Panmure suggests a sum of the parts valuation of Â£6.Meanwhile, HCM has reported a reasonable set of interims driven by its Chinese consumer healthcare arm. Overall sales rose 14% to US$83.3m and pretax loss after head office costs was US$1.4m and a loss per share of 2.8 cents. Of course, most of this has to do with the fact that HCM has been spending all the profits it makes from its core healthcare division on the R&D side.Th ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

YouGov

Capital Drilling

Hutchison China Meditech -NÃ©stle deal for HMPL-004 drug (January 2013)

Hutchison China Meditech (September 2012)

Hutchison China Meditech - 2012 starts with a bang (April 2012)

Hutchison China Meditech (March 2012)

Hutchison China Meditech - Nets US$20m upfront collaboration payment from Astra Zeneca (January 2012)

Hutchison China Meditech - To distribute third party drugs (August 2011)

Hutchison China Meditech (April 2011)

Hutchison China Meditech - Pre-IPO funding ahead of NASDAQ float? (January 2011)

Hutchison China Meditech (October 2010)

Hutchison China Meditech - Out-licensing deal for lead product imminent (September 2010)

Hutchison China Meditech - Great secrecy shrouds R&D division (July 2010)

Hutchison China Meditech - 17 of 307 Chinese "essential medicines" (June 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X